# Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

> **NCT04900428** · PHASE2 · TERMINATED · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 179 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** COVI-DROPS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04900428
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-16
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-05-06
- **Target enrollment:** 179 (ACTUAL)
- **Why stopped:** Study was terminated at interim analysis due to drops not working on new variants
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04900428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04900428, "Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04900428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*